S. de Vogel

First name
S.
Last name
de Vogel
Margulis, A. V., Fortuny, J., Kaye, J. A., Calingaert, B., Reynolds, M., Plana, E., et al. (2018). Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom. Epidemiology. http://doi.org/10.1097/ede.0000000000000856
Margulis, A. V., Fortuny, J., Kaye, J. A., Calingaert, B., Reynolds, M., Plana, E., et al. (2018). Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom. Epidemiology. http://doi.org/10.1097/ede.0000000000000786
Arana, A., Margulis, A. V., Varas-Lorenzo, C., Bui, C. L., Gilsenan, A., McQuay, L. J., et al. (2020). Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5150
Heintjes, E. M., Bezemer, I. D., Prieto-Alhambra, D., Smits, E., Booth, H. P., Dedman, D., et al. (2020). Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries. Clin Epidemiol. http://doi.org/10.2147/clep.s242065
Phiri, K., Hallas, J., Linder, M., Margulis, A., Suehs, B., Arana, A., et al. (2021). A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Curr Med Res Opin. http://doi.org/10.1080/03007995.2021.1891035
Hoffman, V., Hallas, J., Linder, M., Margulis, A. V., Suehs, B. T., Arana, A., et al. (2021). Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-021-01095-7